



US009408922B2

(12) **United States Patent**
Gardner, II et al.

(10) **Patent No.:** **US 9,408,922 B2**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **ANTI-TOFACITINIB ANTIBODIES AND USES THEREOF FOR DRUG MONITORING**

(71) Applicant: **Pfizer Inc.**, New York, NY (US)

(72) Inventors: **Joseph Paul Gardner, II**, Colchester, CT (US); **Victoria Yatsum Wong**, East Lyme, CT (US)

(73) Assignee: **Pfizer Inc.**, New York, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 32 days.

(21) Appl. No.: **14/411,356**

(22) PCT Filed: **Jun. 18, 2013**

(86) PCT No.: **PCT/IB2013/055008**

§ 371 (c)(1),
(2) Date: **Dec. 24, 2014**

(87) PCT Pub. No.: **WO2014/001967**

PCT Pub. Date: **Jan. 3, 2014**

(65) **Prior Publication Data**

US 2015/0337054 A1 Nov. 26, 2015

Related U.S. Application Data

(60) Provisional application No. 61/665,361, filed on Jun. 28, 2012.

(51) **Int. Cl.**
C07K 16/44 (2006.01)
A61K 47/48 (2006.01)
G01N 33/94 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 47/48284** (2013.01); **A61K 47/4833** (2013.01); **C07K 16/44** (2013.01); **G01N 33/9493** (2013.01); **C07K 2317/10** (2013.01); **C07K 2317/30** (2013.01); **C07K 2317/33** (2013.01); **C07K 2317/56** (2013.01); **C07K 2317/565** (2013.01); **C07K 2317/92** (2013.01)

(58) **Field of Classification Search**
CPC A61K 47/48284; A61K 47/4833; G01N 33/9493
See application file for complete search history.

(56) **References Cited**
PUBLICATIONS

Paniagua et al., "Quantitative analysis of the immunosuppressant CP-690,550 in whole blood by column-switching high-performance liquid chromatography and mass spectrometry detection." *Therapeutic Drug Monitoring*, vol. 27, No. 5, p. 608-616, 2005.
Tamura et al., "A Highly sensitive method to assay FK-506 levels in plasma." *Transplantation Proceedings*, vol. 19, No. 5, p. 23-29, 1987.
Matsumoto et al., "Preparation of antibodies against a novel immunosuppressant, FTY720, and development of an enzyme immunoassay for FTY720." *Bioorganic & medicinal Chemistry*, vol. 14, No. 12, p. 4182-4192, 2006.
Clementi et al., "Antibodies Against Small Molecules", *Annali Dell'istituto Superiore Di Sanita, Rome*, vol. 27, No. 1, p. 139-144, 1991.
Flanagan et al., "Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection." *J. of Medicinal Chemistry, American Chemical Society*, vol. 53, No. 24, p. 8468-8487, 2010.
Lefranc, et al., "IMGT, the international ImMunoGeneTics database." *Nucleic Acids Res.*, vol. 27, No. 1 p. 209-212, 1999.
MacCallum et al., "Antibody-antigen Interactions: Contact Analysis and Binding Site Topography." *J. Molecular Biol.*, vol. 262, p. 732-745, 1996.
Makabe et al., "Thermodynamic Consequences of Mutations in Verrier Zone Residues of a Humanized Anti-human Epidermal Growth Factor Receptor Murine Antibody, 528." *J. Biological Chemistry*, vol. 283, No. 2, p. 1156-1166, 2008.

Primary Examiner — Shafiqul Haq
(74) *Attorney, Agent, or Firm* — Pfizer Patent Department; Raquel M. Alvarez

(57) **ABSTRACT**
The invention provides selective tofacitinib antibodies, immunogenic tofacitinib conjugates that are useful as immunogenic molecules for the generation of antibodies specific for tofacitinib, along with methods for measuring the concentration of tofacitinib in a sample, processes for making the antibodies, and assays and kits for using the antibodies.

23 Claims, 5 Drawing Sheets